Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Vinnard

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
International Journal of Molecular Sciences|December 23, 2022
Ultrasensitive Detection of Multidrug-Resistant <i>Mycobacterium tuberculosis</i> Using SuperSelective Primer-Based Real-Time PCR AssaysAnshika Narang, Salvatore A E Marras, Natalia Kurepina, et al.
Respiratory Medicine|December 5, 2018
Relative risk of all-cause mortality in patients with nontuberculous mycobacterial lung disease in a US managed care populationTheodore K Marras, Christopher Vinnard, Quanwu Zhang, et al.
Mbio|September 1, 2016
Colistin- and Carbapenem-Resistant Escherichia coli Harboring mcr-1 and blaNDM-5, Causing a Complicated Urinary Tract Infection in a Patient from the United StatesJosé R Mediavilla, Amee Patrawalla, Liang Chen, et al.
American Journal of Infection Control|December 4, 2014
Catheter salvage in home infusion patients with central line-associated bloodstream infectionDaniel A Caroff, Anne H Norris, Sara Keller, et al.
The Journal of Antimicrobial Chemotherapy|May 5, 2017
Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TBChristopher Vinnard, Shruthi Ravimohan, Neo Tamuhla, et al.
Plos One|November 3, 2017
Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activationChristopher Vinnard, Shruthi Ravimohan, Neo Tamuhla, et al.
Frontiers in Pharmacology|August 28, 2020
Redox Imbalance and Oxidative DNA Damage During Isoniazid Treatment of HIV-Associated Tuberculosis: A Clinical and Translational Pharmacokinetic StudyIsaac Zentner, Hyun-Moon Back, Leonid Kagan, et al.
British Journal of Clinical Pharmacology|October 30, 2016
Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activationChristopher Vinnard, Shruthi Ravimohan, Neo Tamuhla, et al.
Clinical and Translational Science|January 20, 2023
First-in-human study with SAR445088: A novel selective classical complement pathway inhibitorTimothy Chow, Pirouz Shamszad, Christopher Vinnard, et al.
The Journal of Antimicrobial Chemotherapy|July 6, 2019
Optimizing ethambutol dosing among HIV/tuberculosis co-infected patients: a population pharmacokinetic modelling and simulation studyKrina Mehta, Shruthi Ravimohan, Jotam G Pasipanodya, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
International Journal of Molecular Sciences|December 23, 2022
Ultrasensitive Detection of Multidrug-Resistant <i>Mycobacterium tuberculosis</i> Using SuperSelective Primer-Based Real-Time PCR AssaysAnshika Narang, Salvatore A E Marras, Natalia Kurepina, et al.
Respiratory Medicine|December 5, 2018
Relative risk of all-cause mortality in patients with nontuberculous mycobacterial lung disease in a US managed care populationTheodore K Marras, Christopher Vinnard, Quanwu Zhang, et al.
Mbio|September 1, 2016
Colistin- and Carbapenem-Resistant Escherichia coli Harboring mcr-1 and blaNDM-5, Causing a Complicated Urinary Tract Infection in a Patient from the United StatesJosé R Mediavilla, Amee Patrawalla, Liang Chen, et al.
American Journal of Infection Control|December 4, 2014
Catheter salvage in home infusion patients with central line-associated bloodstream infectionDaniel A Caroff, Anne H Norris, Sara Keller, et al.
The Journal of Antimicrobial Chemotherapy|May 5, 2017
Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TBChristopher Vinnard, Shruthi Ravimohan, Neo Tamuhla, et al.
Plos One|November 3, 2017
Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activationChristopher Vinnard, Shruthi Ravimohan, Neo Tamuhla, et al.
Frontiers in Pharmacology|August 28, 2020
Redox Imbalance and Oxidative DNA Damage During Isoniazid Treatment of HIV-Associated Tuberculosis: A Clinical and Translational Pharmacokinetic StudyIsaac Zentner, Hyun-Moon Back, Leonid Kagan, et al.
British Journal of Clinical Pharmacology|October 30, 2016
Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activationChristopher Vinnard, Shruthi Ravimohan, Neo Tamuhla, et al.
Clinical and Translational Science|January 20, 2023
First-in-human study with SAR445088: A novel selective classical complement pathway inhibitorTimothy Chow, Pirouz Shamszad, Christopher Vinnard, et al.
The Journal of Antimicrobial Chemotherapy|July 6, 2019
Optimizing ethambutol dosing among HIV/tuberculosis co-infected patients: a population pharmacokinetic modelling and simulation studyKrina Mehta, Shruthi Ravimohan, Jotam G Pasipanodya, et al.
Pageof 5